Helen Heslop is professor of medicine and pediatrics at Baylor College of Medicine, and also directs the Adult Stem Cell Transplant Program at The Methodist Hospital. She is also associate director for clinical research at the Dan L. Duncan Cancer Center.
Dr. Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. Her initial studies were the first to demonstrate that antigen-specific cytotoxic T cells could eradicate an established malignancy and because the cells were genetically marked, she and her collaborators obtained definitive evidence of cell expansion, trafficking to tumor sites and decade-long persistence. Subsequent protocols have extended this approach to Hodgkin’s Disease, NHL and nasopharyngeal cancer. An additional focus in reconstituting antiviral immunity post-transplant and she has led an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She, therefore, has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently holds 10 INDs and has also obtained orphan drug designation for her initial study.
Dr. Heslop is a Doris Duke distinguished clinical research scientist and serves as principal investigator on several peer-reviewed research programs, including an NCI-funded program project grant (Enhancing T-Cell Therapy of Cancer) a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) award (Immunotherapy of Lymphoma) and a SPORE in lymphoma from the NCI. She is also the principal investigator on an NHLBI-funded training grant in Cell and Gene Therapy. She is the current president of the Foundation for Accreditation of Cell Therapy (FACT).